Your browser is no longer supported. Please, upgrade your browser.
Finch Therapeutics Group, Inc.
Index- P/E- EPS (ttm)- Insider Own6.80% Shs Outstand47.23M Perf Week4.44%
Market Cap708.71M Forward P/E- EPS next Y-7.79 Insider Trans5.83% Shs Float24.07M Perf Month-4.87%
Income- PEG- EPS next Q-0.28 Inst Own14.30% Short Float1.41% Perf Quarter3.35%
Sales9.48M P/S74.76 EPS this Y-89.60% Inst Trans0.03% Short Ratio4.21 Perf Half Y-
Book/sh5.07 P/B2.74 EPS next Y-17.60% ROA- Target Price- Perf Year-
Cash/sh3.78 P/C3.67 EPS next 5Y- ROE- 52W Range11.56 - 22.50 Perf YTD-34.90%
Dividend- P/FCF- EPS past 5Y- ROI42.00% 52W High-38.31% Beta-
Dividend %- Quick Ratio17.20 Sales past 5Y- Gross Margin- 52W Low20.07% ATR1.21
Employees131 Current Ratio17.20 Sales Q/Q98.30% Oper. Margin- RSI (14)46.16 Volatility8.40% 8.21%
OptionableNo Debt/Eq0.01 EPS Q/Q- Profit Margin- Rel Volume0.32 Prev Close13.88
ShortableYes LT Debt/Eq0.01 Earnings- Payout- Avg Volume80.62K Price13.88
Recom1.00 SMA20-5.33% SMA50-4.68% SMA200-5.70% Volume0 Change0.00%
Apr-13-21Initiated Jefferies Buy $29
Apr-13-21Initiated Evercore ISI Outperform $34
Apr-13-21Initiated BofA Securities Buy $25
Jun-28-21 07:00AM  
May-28-21 07:00AM  
May-13-21 07:00AM  
May-06-21 07:00AM  
Apr-27-21 07:00AM  
Mar-19-21 04:25PM  
Mar-18-21 10:32PM  
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and FIN-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and crohn's disease. The company has collaboration and license agreements with Millennium Pharmaceuticals, Inc.; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FERRANTE DOMENIC JDirectorMar 23Buy17.00102,9411,749,997636,195Mar 25 06:04 PM
SMISEK JEFFERY ADirectorMar 23Buy17.0088,2351,499,9951,694,541Mar 25 06:08 PM